Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 1, 2016, Pages 50-59

  Roche Molina, Marta ^a   Sanz Rosa, David ^a   Cruz, Francisco M ^a   García Prieto, Jaime ^a   López, Sergio ^b   Abia, Rocío ^b   Muriana, Francisco J G ^b   Fuster, Valentín ^a,c   Ibáñez, Borja ^a,d   Bernal, Juan A ^a  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b INSTITUTO DE LA GRASA   (Spain)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Atherosclerosis; hypercholesterolemia; PCSK9

Indexed keywords

APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; CHOLESTEROL; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ADENO ASSOCIATED VIRUS; ADULT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; GAIN OF FUNCTION MUTATION; GENE INTERACTION; GENE TRANSFER; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNE RESPONSE; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; LIVER INJURY; MACROPHAGE; MOUSE; NONHUMAN; VIRUS PARTICLE; 129 MOUSE; ANIMAL; AORTA; AORTA DISEASE; ATHEROSCLEROTIC PLAQUE; BLOOD; C57BL MOUSE; DEFICIENCY; DEPENDOPARVOVIRUS; DISEASE MODEL; ENZYMOLOGY; GENE VECTOR; GENETICS; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; MUTATION; PATHOLOGY; TIME;

ANIMALS; AORTA; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL; DEPENDOVIRUS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; PLAQUE, ATHEROSCLEROTIC; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TIME FACTORS;

EID: 84920140051     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303617     Document Type: Article

References (49)

1. Domanski M, Lloyd-Jones D, Fuster V, Grundy S. Can we dramatically reduce the incidence of coronary heart disease? Nat Rev Cardiol. 2011;8:721-725.
2. Fuster JJ, Castillo AI, Zaragoza C, Ibáñez B, Andrés V. Animal models of atherosclerosis. Prog Mol Biol Transl Sci. 2012;105:1-23.
3. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341-355.
4. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104:503-516.
5. Ishibashi S, Herz J, Maeda N, Goldstein JL, Brown MS. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci USA. 1994;91:4431-4435.
6. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-defcient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
7. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993;92:883-893.
8. Li J, Tumanut C, Gavigan JA, Huang WJ, Hampton EN, Tumanut R, Suen KF, Trauger JW, Spraggon G, Lesley SA, Liau G, Yowe D, Harris JL. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J. 2007;406:203-207.
9. Dubuc G, Tremblay M, Paré G, Jacques H, Hamelin J, Benjannet S, Boulet L, Genest J, Bernier L, Seidah NG, Davignon J. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res. 2010;51:140-149.
10. Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with auto-somal dominant hypercholesterolemia. Clin Genet. 2004;65:419-422.
11. Phan BA, Toth PP. Is the future of statins aligned with new novel lipid modulation therapies? Curr Atheroscler Rep. 2013;15:300.
12. Denis M, Marcinkiewicz J, Zaid A, Gauthier D, Poirier S, Lazure C, Seidah NG, Prat A. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation. 2012;125:894-901.
13. Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA. 2004;101:7100-7105.
14. Abboud S, Karhunen PJ, Lütjohann D, Goebeler S, Luoto T, Friedrichs S, Lehtimaki T, Pandolfo M, Laaksonen R. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PLoS One. 2007;2:e1043.
15. Abifadel M, Guerin M, Benjannet S, et al. Identifcation and characterization of new gain-of-function mutations in the PCSK9 gene responsible for auto-somal dominant hypercholesterolemia. Atherosclerosis. 2012;223:394-400.
16. Tang Z, Jiang L, Peng J, Ren Z, Wei D, Wu C, Pan L, Jiang Z, Liu L. Pcsk9 sirna suppresses the infammatory response induced by oxldl through inhibition of nf-kappab activation in thp-1-derived macrophages. Int J Mol Med. 2012;30:931-938
17. Timms KM, Wagner S, Samuels ME, Forbey K, Goldfne H, Jammulapati S, Skolnick MH, Hopkins PN, Hunt SC, Shattuck DM. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet. 2004;114:349-353.
18. Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterol-emia. Nat Struct Mol Biol. 2007;14:413-419.
19. Grieger JC, Samulski RJ. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol. 2012;507:229-254.
20. Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res. 2014;114:101-108.
21. Borel F, Kay MA, Mueller C. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther. 2014;22:692-701.
22. Cerrone M, Noorman M, Lin X, Chkourko H, Liang FX, van der Nagel R, Hund T, Birchmeier W, Mohler P, van Veen TA, van Rijen HV, Delmar M. Sodium current defcit and arrhythmogenesis in a murine model of plakophilin-2 haploinsuffciency. Cardiovasc Res. 2012;95:460-468.
23. Mbikay M, Mayne J, Chrétien M. Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions. J Diabetes. 2013;5:391-405.
24. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006;116:2995-3005.
25. Fasano T, Sun XM, Patel DD, Soutar AK. Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. Atherosclerosis. 2009;203:166-171.
26. Herbert B, Patel D, Waddington SN, Eden ER, McAleenan A, Sun XM, Soutar AK. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler Thromb Vasc Biol. 2010;30:1333-1339.
27. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autoso-mal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156.
28. Al-Mashhadi RH, Sørensen CB, Kragh PM, et al. Familial hypercholester-olemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. Sci Transl Med. 2013;5:166ra1.
29. Kourimate S, Chétiveaux M, Jarnoux AL, Lalanne F, Costet P. Cellular and secreted proprotein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes. Atherosclerosis. 2009;206:134-140.
30. Miao CH, Ohashi K, Patijn GA, Meuse L, Ye X, Thompson AR, Kay MA. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther. 2000;1:522-532.
31. Dansky HM, Charlton SA, Sikes JL, Heath SC, Simantov R, Levin LF, Shu P, Moore KJ, Breslow JL, Smith JD. Genetic background determines the extent of atherosclerosis in ApoE-defcient mice. Arterioscler Thromb Vasc Biol. 1999;19:1960-1968.
32. Qiao JH, Xie PZ, Fishbein MC, Kreuzer J, Drake TA, Demer LL, Lusis AJ. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcifcation. Arterioscler Thromb. 1994;14:1480-1497.
33. van Ree JH, van den Broek WJ, Dahlmans VE, Wieringa B, Frants RR, Havekes LM, Hofker MH. Variability in cholesterol content in serum and aortic tissue in apolipoprotein E-defcient mice is comparable in inbred (129/Sv) and outbred (mixed 129/Sv and C57BL/6) mice. Atherosclerosis. 1995;118:165-167.
34. Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specifc low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008;48:646-654.
35. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xan-thomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 1994;93:1885-1893.
36. Kaspar BK, Roth DM, Lai NC, Drumm JD, Erickson DA, McKirnan MD, Hammond HK. Myocardial gene transfer and long-term expression following intracoronary delivery of adeno-associated virus. J Gene Med. 2005;7:316-324.
37. Suhy DA, Kao SC, Mao T, et al. Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model. Mol Ther. 2012;20:1737-1749.
38. Büeler H. Adeno-associated viral vectors for gene transfer and gene therapy. Biol Chem. 1999;380:613-622.
39. Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A pep-tide. Biochem Biophys Res Commun. 2008;375:69-73.
40. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283:2363-2372.
41. Frykman PK, Brown MS, Yamamoto T, Goldstein JL, Herz J. Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. Proc Natl Acad Sci USA. 1995;92:8453-8457.
42. Goudriaan JR, Tacken PJ, Dahlmans VE, Gijbels MJ, van Dijk KW, Havekes LM, Jong MC. Protection from obesity in mice lacking the VLDL receptor. Arterioscler Thromb Vasc Biol. 2001;21:1488-1493.
43. Tacken PJ, Teusink B, Jong MC, Harats D, Havekes LM, van Dijk KW, Hofker MH. LDL receptor defciency unmasks altered VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice. J Lipid Res. 2000;41:2055-2062.
44. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342-347.
45. Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis. 2011;216:258-265.
46. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108-1118.
47. Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013;228:18-28.
48. Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholes-terolemia. Annu Rev Pharmacol Toxicol. 2014;54:273-293.
49. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezeti-mibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29-36.